Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 3/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14511652 | 0.78 | ALOX5 (0.42) | MAPK14GSK3BGCGRMAPK13MAPK12 | |
| SCHEMBL14511643 | 0.77 | TSHR (0.39) | MAPK14GCGRKDM4EHPGD | |
| SCHEMBL14511641 | 0.77 | KDM4E (0.40) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL14511644 | 0.71 | HSD17B10 (0.46) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL5371873 | 0.71 | KDM4E (0.67) | MAPK14GSK3BGCGRMAPK13MAPK12 | |
| SCHEMBL14511640 | 0.69 | ALOX5 (0.51) | MAPK14MAPK13MAPK12MAPK11DHODH | |
| SCHEMBL105263 | 0.66 | LMNA (0.52) | HPGD | |
| SCHEMBL2175497 | 0.66 | MAPK14 (0.40) | MAPK14GSK3BGCGRMAPK13MAPK12 | |
| SCHEMBL14705875 | 0.65 | SMN1; SMN2 (0.49) | MAPK14PDE2AGSK3BGCGRMAPK13 | |
| SCHEMBL14705882 | 0.65 | HAO2 (0.44) | MAPK14PDE2AGSK3BGCGRMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105900-A1 | Pharmaceutical compounds | AURKA, AURKC, CDK1 | TRPV3 3524/4885MAPK14 342/4885PDE2A 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.